[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100174193":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":29,"locations":39,"responsibleParty":51,"collaborators":29,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":29,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":29,"overallStatus":73,"whyStopped":29,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":29,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"BI 1021958","EXPERIMENTAL","Single rising dose (SRD) part",[13],"Drug: BI 1021958",{"label":15,"type":10,"description":16,"interventionNames":17},"BI 1021958 (Food effect)","Food effect part (FE)",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo to BI 1021958","PLACEBO_COMPARATOR","Matching placebo as drinking solution and tablets",[23],"Drug: Placebo to BI 1021958",[25,30,33],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","tablet",[15],null,{"type":26,"name":9,"description":31,"armGroupLabels":32,"otherNames":29},"drinking solution \u002F tablet",[9],{"type":26,"name":19,"description":34,"armGroupLabels":35,"otherNames":29},"SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast",[19],[37],{"name":5,"affiliation":5,"role":38},"STUDY_CHAIR",[40],{"facility":41,"status":29,"city":42,"state":29,"zip":29,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":29},"1310.1.1 Boehringer Ingelheim Investigational Site","Biberach","Germany","DE",{"type":46,"coordinates":47},"Point",[48,49],8.03333,48.33333,{"lat":49,"lon":48},{"type":52,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100174193","phase-1-safety-tolerability-pharmacokinetics-and-early-pharmacodynamics-of-single-rising-oral-doses-of-bi-1021958-tablets-in-healthy-male-volunteers-100174193",false,"NCT01541488","Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 mg as Drinking Solution, and 5, 20, 60, 150, 300, 500 mg as Tablets) of BI 1021958 in Healthy Male Volunteers (Placebo-controlled, Randomised and Single Blind Within Dose Groups), Including Investigation of the Effect of Food on the Bioavailability of BI 1021958 (Open-label, Randomised, Two-way Cross-over)","Inclusion criteria:\n\n1\\. Healthy male subjects\n\nExclusion criteria:\n\n1\\. Any relevant deviation from healthy conditions",true,"MALE","18 Years","45 Years",{"count":65,"type":66},66,"ACTUAL","INTERVENTIONAL",[69],"PHASE1","Safety, tolerability, pharmacokinetics and early pharmacodynamics of single rising oral doses of BI 1021958 tablets in healthy male volunteers (first-in-human trial)",[72],"Healthy","COMPLETED","2013-10-30",{"date":76,"type":77},"2013-10-31","ESTIMATED",{"date":79,"type":29},"2012-02",{"name":5,"class":6},1]